Palvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% – Still a Buy?

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) shot up 5.7% during trading on Friday . The company traded as high as $157.35 and last traded at $156.2260. 45,524 shares were traded during mid-day trading, a decline of 84% from the average session volume of 282,512 shares. The stock had previously closed at $147.77.

Analyst Ratings Changes

A number of research analysts have issued reports on PVLA shares. HC Wainwright upped their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Chardan Capital restated a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Stephens restated an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Finally, Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Stock Performance

The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -37.71 and a beta of -0.20. The company has a 50-day moving average price of $125.26 and a 200-day moving average price of $115.30.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the sale, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Trading of Palvella Therapeutics

A number of large investors have recently made changes to their positions in PVLA. Jennison Associates LLC increased its stake in Palvella Therapeutics by 262.4% during the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after purchasing an additional 280,573 shares in the last quarter. Profund Advisors LLC bought a new position in Palvella Therapeutics in the fourth quarter valued at approximately $608,000. Vanguard Group Inc. boosted its holdings in shares of Palvella Therapeutics by 13.3% in the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after buying an additional 65,960 shares during the period. Lisanti Capital Growth LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $4,341,000. Finally, Emerald Advisers LLC bought a new stake in shares of Palvella Therapeutics during the first quarter worth $20,131,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.